Abstract
Corticosteroids induce apoptosis in both normal and neoplastic lymphocytes. For this reason they are commonly used to treat autoimmune disorders and lymphoid malignancies also. The exact mechanism of corticosteroid-induced apoptosis is not fully understood despite the fact that much has been found in respect to several supposed involved mechanisms. This process is arbitrarily divided in several phases. Firstly, glucocorticoid enters the cell and binds to the glucocorticoid receptor (GR) in the cytoplasm. The GR changes conformation and the heat shock proteins, normally bound to the receptor in the steady state, fall off. The activated GR-hormone complex enters the nucleus and binds to its specific DNA binding site, the glucocorticoid responsive element (GRE), thus resulting in activating or repressing transcription of genes. The activation of caspases or other proteases and endonucleases finally results in the commitment to cell death.
Keywords: Glucocorticoid, apoptosis
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry
Title: Corticoisteroid-Induced Apoptosis in Hematological Malignancies
Volume: 8 Issue: 1
Author(s): Giovanni D'Arena, Nicola Cascavilla, Giovanni Rossi, Aldo Giudice, Claudio Arra, Vincenzo De Feo and Bruno Marcello Fusco
Affiliation:
Keywords: Glucocorticoid, apoptosis
Abstract: Corticosteroids induce apoptosis in both normal and neoplastic lymphocytes. For this reason they are commonly used to treat autoimmune disorders and lymphoid malignancies also. The exact mechanism of corticosteroid-induced apoptosis is not fully understood despite the fact that much has been found in respect to several supposed involved mechanisms. This process is arbitrarily divided in several phases. Firstly, glucocorticoid enters the cell and binds to the glucocorticoid receptor (GR) in the cytoplasm. The GR changes conformation and the heat shock proteins, normally bound to the receptor in the steady state, fall off. The activated GR-hormone complex enters the nucleus and binds to its specific DNA binding site, the glucocorticoid responsive element (GRE), thus resulting in activating or repressing transcription of genes. The activation of caspases or other proteases and endonucleases finally results in the commitment to cell death.
Export Options
About this article
Cite this article as:
D'Arena Giovanni, Cascavilla Nicola, Rossi Giovanni, Giudice Aldo, Arra Claudio, De Feo Vincenzo and Fusco Marcello Bruno, Corticoisteroid-Induced Apoptosis in Hematological Malignancies, Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry 2009; 8 (1) . https://dx.doi.org/10.2174/187152309787580739
DOI https://dx.doi.org/10.2174/187152309787580739 |
Print ISSN 1871-5230 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-614X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
DNA Methyltransferase-1 Inhibitors as Epigenetic Therapy for Cancer
Current Cancer Drug Targets Recent Clinical Trials of mTOR-Targeted Cancer Therapies
Reviews on Recent Clinical Trials Histone Deacetylase Inhibitors in Cancer Treatment: A Review of the Clinical Toxicity and the Modulation of Gene Expression in Cancer Cells
Current Pharmaceutical Biotechnology Drug Target Discovery Through Analysis of Laccase Regulatory Networks of Cryptococccus neoformans
Current Enzyme Inhibition MicroRNAs and Aging: Biomarkers or Therapeutic Targets?
Current Aging Science Recent Developments in Taxane Drug Delivery
Current Drug Delivery The Hsp32 Inhibitors SMA-ZnPP and PEG-ZnPP Exert Major Growth-Inhibitory Effects on CD34+/CD38+ and CD34+/CD38- AML Progenitor Cells
Current Cancer Drug Targets Regulation and Importance of the PI3K/Akt/mTOR Signaling Pathway in Hematologic Malignancies
Anti-Cancer Agents in Medicinal Chemistry Cellular Iron Homeostasis and Therapeutic Implications of Iron Chelators in Cancer
Current Pharmaceutical Biotechnology Phase I Clinical Trial of Exherin (ADH-1) in Patients with Advanced Solid Tumors
Current Clinical Pharmacology Recent Trends in Targeted Anticancer Prodrug and Conjugate Design
Current Medicinal Chemistry Hypoxia Inducible Factor Stabilization As a Novel Strategy to Treat Anemia
Current Medicinal Chemistry Advances in Stem Cell Therapy for Leukemia
Current Stem Cell Research & Therapy Genetics, Gene Expression, and Targeted Therapies in Chronic Lymphocytic Leukemia
Current Drug Targets Epigenetics and Adult Acute Myeloid Leukemia
Current Pharmacogenomics and Personalized Medicine Synthesis of ST7612AA1, a Novel Oral HDAC Inhibitor, via Radical Thioacetic Acid Addition
Current Bioactive Compounds Drug-Drug Interactions of Triazole Antifungal Agents in Multimorbid Patients and Implications for Patient Care
Current Drug Metabolism Clinical and Genetic Features of Warts, Hypogammaglobulinemia, Infections and Myelokathexis (WHIM) Syndrome
Current Molecular Medicine Synthesis, Characterization and Evaluation of Cytotoxicity of New Aminophosphonic Acid Diesters in Human Leukemia Cells
Letters in Drug Design & Discovery Control of Copper Status for Cancer Therapy
Current Cancer Drug Targets